Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd; Bonnie K. Harrington; Susan O’Brien; Jeffrey A. Jones; Anna Schuh; Stephen Devereux; Jorge Chaves; William G. Wierda; Farrukh T. Awan; Jennifer R. Brown; Peter Hillmen; Deborah M. Stephens; Paolo Ghia; Jacqueline C. Barrientos; John M. Pagel; Jennifer A. Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J. Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G. Diacovo; Amy J. Johnson; Richard R. Furman

doi:10.1056/nejmoa1509981

Abstract

This is the authors' abstract. We don't add key points for this paper.

In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Byrd et al. (2015) studied this question.

synapsesocial.com/papers/69dcc8e07873f5f05b134072 https://doi.org/10.1056/nejmoa1509981

View Full Paper

Ask AI

Bookmark

Share

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Abstract

Ask about this paper

Discussion

Cite This Study

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading